Back to User profile » Dr Jingjing Wu

Papers published by Dr Jingjing Wu:

Case Series

Effective Treatment with PD-1 Antibody, Chidamide, Etoposide, and Thalidomide (PCET) for Relapsed/Refractory Natural Killer/T-Cell Lymphoma: A Report of Three Cases

Du L, Zhang L, Li L, Li X, Yan J, Wang X, Fu X, Sun Z, Zhang X, Li Z, Wu J, Yu H, Chang Y, Zhou Z, Nan F, Wu X, Tian L, Zhang M

OncoTargets and Therapy 2020, 13:7189-7197

Published Date: 27 July 2020

Clinical Trial Report

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M

Drug Design, Development and Therapy 2020, 14:275-284

Published Date: 22 January 2020

Original Research

Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens

Zhang F, Li L, Zhang L, Li X, Fu X, Wang X, Wu J, Sun Z, Kong F, Ren L, Zhang M

Blood and Lymphatic Cancer: Targets and Therapy 2019, 9:33-43

Published Date: 19 August 2019

Original Research

Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study

Ma Q, Chang Y, Li L, Li X, Wang X, Wu J, Fu X, Sun Z, Yu H, Zhang X, Zhou Z, Nan F, Li Z, Liu X, Zhao Q, Li Y, Zhang L, Zhang M, Zhang L

Cancer Management and Research 2019, 11:1363-1372

Published Date: 11 February 2019